+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
S

Actively Recruiting

Researchers are studying how certain factors like age, gender, other medical conditions, and the type of immunotherapy affect whether patients with malignant solid tumors develop mild or serious side effects from immune checkpoint inhibitor treatments. This observational study aims to develop and validate a model that predicts severe immune-related side effects during the first year of immunotherapy, while also assessing quality of life and adverse events over 12 months. The study is sponsored by the SWOG Cancer Research Network and includes translational medicine goals such as evaluating cytokine levels as predictors and establishing a tissue and blood sample repository. Participants will provide a tissue sample at the start of their routine cancer treatment and complete questionnaires at multiple time points at treatment start, and weeks 4, 12, 24, and 52. They may also provide optional blood samples during the study. This design allows researchers to monitor immune-related side effects and patient-reported outcomes over time. During the study, participants will complete various questionnaires to report their quality of life, cognitive function, and side effects. Blood and tissue samples will be analyzed to explore predictive markers of toxicity. Researchers will track the occurrence of severe immune-related side effects over 52 weeks and assess changes in patient-reported outcomes. The study includes ongoing monitoring and data collection, with participation lasting approximately one year from treatment start.

Age: 18Years +All Genders
849 locations
T

Actively Recruiting

Researchers are evaluating a text-based smoking cessation program for rural cancer survivors who smoke. This phase III trial compares an eight-week scheduled gradual reduction program paired with supportive text messages to a control intervention using an informational booklet. The study aims to assess which method better helps these patients quit smoking, with a focus on improving quality of life. The trial targets adults diagnosed with cancer within the past 10 years who currently smoke at least five cigarettes daily and live in rural areas. Participants are randomly assigned to one of two groups. One group follows a personalized eight-week gradual reduction schedule for smoking, supported by 12 weeks of cessation text messages. The other group receives the National Cancer Institutes Clearing the Air booklet to assist with quitting plans. Both groups are followed for six months after their quit date to evaluate outcomes. During the study, participants complete assessments including biochemical validation of smoking cessation up to six months post-quit date. Quality of life is measured at baseline, 30 days, and six months after quitting. Participants provide urine samples and must have texting capability on a phone to receive intervention messages. Safety and progress are monitored throughout, with the total participation lasting up to six months post-quit date.

Age: 18Years +All GendersPhase 3
224 locations
E

Actively Recruiting

Researchers are evaluating a combination therapy for adults with newly diagnosed multiple myeloma not intended for early autologous transplantation. This phase III trial compares a four-drug regimen including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug regimen of daratumumab, lenalidomide, and dexamethasone. The study aims to determine if adding bortezomib improves overall survival and progression-free survival in patients with different minimal residual disease statuses, while also assessing side effects and patient-reported outcomes. All participants first receive standard induction therapy with daratumumab given subcutaneously on specific days, lenalidomide orally daily for 21 days, and dexamethasone orally on certain days, repeated every 28 days for 9 cycles. After induction, patients are randomly assigned to one of two consolidation and maintenance arms one adding bortezomib to the consolidation phase followed by maintenance with daratumumab and lenalidomide, and the other continuing with daratumumab, lenalidomide, and dexamethasone for consolidation and maintenance. Treatments continue in cycles of 28 days unless disease progresses or unacceptable side effects occur. During the study, participants undergo various assessments including bone marrow aspirates, blood tests, imaging with PETCT scans, and patient-reported quality of life evaluations. Researchers monitor overall survival, progression-free survival, response rates, adverse events, and neuropathy symptoms over periods up to 15 years. Follow-up visits occur every 3 months for up to 2 years, then less frequently, ensuring long-term monitoring of treatment effects and safety.

Age: 18Years +All GendersPhase 3
647 locations